Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Gene therapy of SCID-X1].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz - 1 Dec 2007

Baum C, Schambach A, Modlich U, Thrasher A

Abstract excerpt

X-linked severe combined immunodeficiency (SCID-X1) is an inherited disease caused by inactivating mutations in the gene encoding the interleukin 2 receptor common gamma chain (IL2RG), which is located on the X-chromosome. Affected boys fail to develop two major effector cell types of the immune system (T cells and NK cells) and suffer from a functional B cell defect. Although drugs such as antibiotics can offer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Targeting
Share to Genetic Predisposition to Disease
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Practice Patterns, Physicians'

Share to Treatment Outcome

Source

Identifiers

PMID: 18046520
DOI: 10.1007/s00103-007-0385-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Gene therapy of SCID-X1].PMID 18046520Read ↗

[Gene therapy of X-linked severe combined immunologic deficiency (SCID-X1)].Semantic proximity Read ↗

Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency DiseaseSemantic proximity Read ↗

Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?Semantic proximity Read ↗

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.Semantic proximity Read ↗

Preclinical ex vivo IL2RG gene therapy using autologous hematopoietic stem cells as an effective and safe treatment for X-linked severe combined immunodeficiency diseaseSemantic proximity Read ↗

Gene therapy for severe combined immune deficiencySemantic proximity Read ↗

Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined ImmunodeficiencySemantic proximity Read ↗

Gene therapy for severe combined immunodeficiencies and beyondSemantic proximity Read ↗

Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.Semantic proximity Read ↗

Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia.Semantic proximity Read ↗

Gene therapy for severe combined immunodeficiency.Semantic proximity Read ↗

Clinical Applications of Gene Therapy for Primary ImmunodeficienciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.